Key takeaways
Foundayo (orforglipron) and Trulicity (dulaglutide) are both medications in the GLP-1 agonist class, used to help manage weight and blood sugar levels, respectively. Foundayo is specifically approved for weight loss in adults who are obese or overweight with a weight-related condition, while Trulicity is approved for managing Type 2 diabetes in people 10 years and older and reducing heart-related risks in adults with Type 2 diabetes. Foundayo is taken orally once a day, whereas Trulicity is injected once a week. Foundayo is not approved for children, while Trulicity can be used by children 10 years and older. Common side effects for both include nausea and stomach issues, but Foundayo also lists constipation and diarrhea as frequent side effects, while Trulicity may cause low appetite and fatigue. Both medications carry a potential risk for thyroid cancer and are not recommended for people with a history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.
